News

SNMMI Announces Ones to Watch 2025 Selections

SNMMI has named its 2025 "Ones to Watch," recognizing rising stars in nuclear medicine and molecular imaging. Honorees will be celebrated at the SNMMI Annual Meeting in June 2025.

Effective Treatment of Disseminated Prostate Cancer Using CD46-Targeted 225Ac Therapy - Beyond the Abstract

A UCSF-led study demonstrates that CD46-targeted alpha therapy using Actinium-225 effectively treats metastatic prostate cancer, especially in tumors lacking PSMA. The therapy shows strong results in eradicating small tumors and improving survival, supporting its potential for clinical use.

How often does post-treatment SPECT/CT impact patient management during Radiopharmaceutical Prostate Cancer Treatment

Impact of Posttreatment SPECT/CT on Patient Management During 177Lu-PSMA-617 Radiopharmaceutical Therapy, published in Journal of Nuclear Medicine, the study revealed that nearly 50% of patients experienced a change in management based on posttreatment SPECT/CT.

Measuring Where Radiopharmaceuticals Concentrate with Digital Autoradiography

3D small-scale dosimetry and tumor control of 225Ac radiopharmaceuticals for prostate cancer, published in Scientific Reports, explores methods of measuring the spatial dose distribution of radiopharmaceuticals in organs and tumors, to inform treatment dose prescription and reduce off-target…